WebDec 2, 2024 · Glycogen synthase kinase 3 (GSK3) has been identified as a promising target for the treatment of Alzheimer’s disease (AD), where … WebNational Center for Biotechnology Information
Kinase Inhibitors Involved in the Regulation of Autophagy: …
WebIt is believed that glycogen synthase kinase-3 (GSK-3) hyperphosphorylates tau protein in progressive supranuclear palsy (PSP). The Tau Restoration on PSP (TAUROS) study … WebApr 1, 2024 · LY2090314, an ATP-competitive intravenous GSK3α/β inhibitor [ 76 ], has been tested in a phase II clinical trial in patients with acute myelogenous leukemia (AML). Although the drug displayed an acceptable safety profile, the clinical benefit was extremely limited as monotherapy [ 77 ]. christopher martin endocrinology
GSK3 INHIBITORS IN CLINICAL TRIAL Download Table
WebSep 1, 2024 · Consistently, pharmacologic inhibition of GSK3β was shown to upregulate β-catenin and c-Myc levels, as well as suppress tumor growth in KRas-mutant PDAC and non-small lung cancer models ( Kazi et al., 2024 ). Interestingly, it has been recently observed that GSK3β plays a key role in modulating cell cycle progression at different regulatory … WebOct 12, 2024 · In vitro validation of GSK3β inhibitors predicted using Assay Central. Potential inhibitors were selected for in vitro testing for GSK3β inhibition using the Promega ADP-Glo assay. All inhibitors were tested at 100 μM ( n = 3), except for the known GSK3β inhibitor staurosporine. WebIn 2024, a screen by Hou et al. found that loss of the genes SPRY3 and GSK3 drives resistance to FLT3-inhibition in acute myeloid leukemia (AML) (Hou et al., 2024). FLT3-inhibitors are currently in clinical trials as a monotherapy and in combination with chemotherapy for the treatment of AML. However, many patients ultimately develop … get to know me scavenger hunt